1<p>Baseline vs. post-Rx.</p>2<p>Appropriate response vs. Poor response.</p><p>ARR: annual relapse rate.</p><p>Rx: IFN-β treatment.</p
<p>One-sided 99% CI (upper-limit, U<sub>L</sub> = 1.63), and one-sided 95% CI (U<sub>L</sub> = 1.45)...
<p>Evaluable subjects are those who at end-of-treatment have not met other unsatisfactory endpoints....
<p>* p = 0.041, compared to FGS only.</p><p>Recurrence rate of PDOX in each treatment group.</p
<p>One-sided 99% CI of the 0.67 ratio (upper-limit, U<sub>L</sub> = 1.12), represents an effect of A...
<p>ARR: annualized relapse rate; EDSS: expanded disability status scale</p><p>Clinical characteristi...
<p>Comparison of AFP levels at baseline and at 4–8 weeks following first-line treatment, based on tr...
<p>Comparisons of the mean of EDSSp post-interferon-β therapy between groups.</p
<p>A. Annualized relapse, rate (ARR) during the first year of fingolimod treatment compared to the y...
<p>Within group comparison compares the relapse rate before and after the switch for each group. The...
<p>Sensitivity analyses of 6-month confirmed EDSS progression in months 13–24 compared with months 2...
<p>Comparison of Readmission Rate (RR) for Patients with (YF) and without (NF) follow-up visits on o...
Comparison of clinical characteristics between the DAS and US remission groups and the non-remission...
<p>Abbreviations: AZA, azathioprine; IFN, interferon.</p>1<p>P-values for AZA vs. IFN comparison wer...
A prospective, open-label treatment trial to compare the effect of IFN b-1a (Avonex), IFNb-1b (Betas...
The decision to use interferon beta (IFN-b) as a treatment for relapsing-remitting multiple sclerosi...
<p>One-sided 99% CI (upper-limit, U<sub>L</sub> = 1.63), and one-sided 95% CI (U<sub>L</sub> = 1.45)...
<p>Evaluable subjects are those who at end-of-treatment have not met other unsatisfactory endpoints....
<p>* p = 0.041, compared to FGS only.</p><p>Recurrence rate of PDOX in each treatment group.</p
<p>One-sided 99% CI of the 0.67 ratio (upper-limit, U<sub>L</sub> = 1.12), represents an effect of A...
<p>ARR: annualized relapse rate; EDSS: expanded disability status scale</p><p>Clinical characteristi...
<p>Comparison of AFP levels at baseline and at 4–8 weeks following first-line treatment, based on tr...
<p>Comparisons of the mean of EDSSp post-interferon-β therapy between groups.</p
<p>A. Annualized relapse, rate (ARR) during the first year of fingolimod treatment compared to the y...
<p>Within group comparison compares the relapse rate before and after the switch for each group. The...
<p>Sensitivity analyses of 6-month confirmed EDSS progression in months 13–24 compared with months 2...
<p>Comparison of Readmission Rate (RR) for Patients with (YF) and without (NF) follow-up visits on o...
Comparison of clinical characteristics between the DAS and US remission groups and the non-remission...
<p>Abbreviations: AZA, azathioprine; IFN, interferon.</p>1<p>P-values for AZA vs. IFN comparison wer...
A prospective, open-label treatment trial to compare the effect of IFN b-1a (Avonex), IFNb-1b (Betas...
The decision to use interferon beta (IFN-b) as a treatment for relapsing-remitting multiple sclerosi...
<p>One-sided 99% CI (upper-limit, U<sub>L</sub> = 1.63), and one-sided 95% CI (U<sub>L</sub> = 1.45)...
<p>Evaluable subjects are those who at end-of-treatment have not met other unsatisfactory endpoints....
<p>* p = 0.041, compared to FGS only.</p><p>Recurrence rate of PDOX in each treatment group.</p
DOI
Add to ORKG